Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
January 16, 2015
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
E Laas, P Mallon, M Delomenie, et al.
British Journal of Cancer
|
September 18, 2015
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
L Rossi, E Laas, P Mallon, et al.
Cancer Letters
|
November 2, 2001
ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma
I Bièche, P Onody, F Lerebours, et al.
Breast (Edinburgh, Scotland)
|
November 26, 2020
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
B Porte, M Carton, F Lerebours, et al.
Lancet (London, England)
|
September 24, 2002
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
P Bertheau, F Plassa, M Espié, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 12, 2011
[Role of locoregional radiation therapy in breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. The Institut Curie-Hôpital René-Huguenin experience]
R Le Scodan, S Bruant, J Selz, et al.
Breast Cancer Research and Treatment
|
September 6, 2019
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database
E Kaczmarek, C Saint-Martin, J-Y Pierga, et al.
Journal of Advanced Research
|
December 28, 2020
Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
F Lerebours, S Vacher, J M Guinebretiere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer
A-S Hamy, J-Y Pierga, A Sabaila, et al.
British Journal of Cancer
|
November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
P H Cottu, J M Extra, M Espie, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
January 16, 2015
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
E Laas, P Mallon, M Delomenie, et al.
British Journal of Cancer
|
September 18, 2015
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
L Rossi, E Laas, P Mallon, et al.
Cancer Letters
|
November 2, 2001
ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma
I Bièche, P Onody, F Lerebours, et al.
Breast (Edinburgh, Scotland)
|
November 26, 2020
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
B Porte, M Carton, F Lerebours, et al.
Lancet (London, England)
|
September 24, 2002
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
P Bertheau, F Plassa, M Espié, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 12, 2011
[Role of locoregional radiation therapy in breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. The Institut Curie-Hôpital René-Huguenin experience]
R Le Scodan, S Bruant, J Selz, et al.
Breast Cancer Research and Treatment
|
September 6, 2019
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database
E Kaczmarek, C Saint-Martin, J-Y Pierga, et al.
Journal of Advanced Research
|
December 28, 2020
Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
F Lerebours, S Vacher, J M Guinebretiere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer
A-S Hamy, J-Y Pierga, A Sabaila, et al.
British Journal of Cancer
|
November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
P H Cottu, J M Extra, M Espie, et al.
Page
of 5